Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052568 · ClinicalTrials.gov registry record · Phase 1
Effects of Psilocybin in Anorexia Nervosa
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04052568: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04052568 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04052568, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2023-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04052568
The ClinicalTrials.gov registry entry for NCT04052568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT04052568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04052568 about?
NCT04052568 is a clinical study titled "Effects of Psilocybin in Anorexia Nervosa". This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators...
What is the current status of trial NCT04052568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-08-26. Estimated completion is 2023-04-20.
What interventions are being tested in trial NCT04052568?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04052568?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.